Loading
Adding the metabolism drug devimistat to FOLFIRINOX did not help people with metastatic pancreatic cancer live longer.
AVENGER 500 was an open-label phase 3 trial in previously untreated metastatic pancreatic adenocarcinoma comparing modified FOLFIRINOX with devimistat against modified FOLFIRINOX alone. The primary endpoint was overall survival. The trial did not show a survival benefit, and response rates were similar between arms, closing the pancreatic programme for devimistat.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Pancreatic cancer: the failed and stopped programmes and why, FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Pancreatic cancer: the failed and stopped programmes and why, FOLFIRINOX / mFOLFIRINOX, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares FOLFIRINOX / mFOLFIRINOX, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.